Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorbald van Hall

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Current Opinion in Immunology|February 8, 2011
Strategies to counteract MHC-I defects in tumorsMargit H Lampen, Thorbald van Hall
Frontiers in Immunology|June 23, 2015
Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to RomeCláudia C Oliveira, Thorbald van Hall
Current Opinion in Immunology|January 18, 2020
To TAP or not to TAP: alternative peptides for immunotherapy of cancerKoen A Marijt, Thorbald van Hall
Molecular Immunology|November 28, 2012
Importance of TAP-independent processing pathwaysClaudia C Oliveira, Thorbald van Hall
Oncoimmunology|June 22, 2012
Infiltrating CTLs are bothered by HLA-E on tumorsMarloes J M Gooden, Thorbald van Hall
International Journal of Molecular Sciences|September 10, 2021
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the SpotlightsMarieke F Fransen, Thorbald van Hall, Ferry Ossendorp
Advances in Immunology|March 28, 2012
Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivityThorbald van Hall, Sjoerd H van der Burg
Molecular Immunology|April 9, 2018
TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I<sup>low</sup> cancersKoen A Marijt, Elien M Doorduijn, Thorbald van Hall
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2020
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor MicroenvironmentLinda Borst, Sjoerd H van der Burg, Thorbald van Hall
Oncoimmunology|August 17, 2017
PD-L1 immune suppression in cancer: Tumor cells or host cells?Jan Willem Kleinovink, Thorbald van Hall, Ferry Ossendorp, et al.
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Current Opinion in Immunology|February 8, 2011
Strategies to counteract MHC-I defects in tumorsMargit H Lampen, Thorbald van Hall
Frontiers in Immunology|June 23, 2015
Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to RomeCláudia C Oliveira, Thorbald van Hall
Current Opinion in Immunology|January 18, 2020
To TAP or not to TAP: alternative peptides for immunotherapy of cancerKoen A Marijt, Thorbald van Hall
Molecular Immunology|November 28, 2012
Importance of TAP-independent processing pathwaysClaudia C Oliveira, Thorbald van Hall
Oncoimmunology|June 22, 2012
Infiltrating CTLs are bothered by HLA-E on tumorsMarloes J M Gooden, Thorbald van Hall
International Journal of Molecular Sciences|September 10, 2021
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the SpotlightsMarieke F Fransen, Thorbald van Hall, Ferry Ossendorp
Advances in Immunology|March 28, 2012
Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivityThorbald van Hall, Sjoerd H van der Burg
Molecular Immunology|April 9, 2018
TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I<sup>low</sup> cancersKoen A Marijt, Elien M Doorduijn, Thorbald van Hall
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2020
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor MicroenvironmentLinda Borst, Sjoerd H van der Burg, Thorbald van Hall
Oncoimmunology|August 17, 2017
PD-L1 immune suppression in cancer: Tumor cells or host cells?Jan Willem Kleinovink, Thorbald van Hall, Ferry Ossendorp, et al.
Pageof 13